The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3301-3303

  Gershenwald, Jeffrey E ^a   Coit, Daniel G ^b   Sondak, Vernon K ^c,d   Thompson, John F ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL PRACTICE; CUTANEOUS MELANOMA; HUMAN; LYMPH NODE DISSECTION; PRACTICE GUIDELINE; PRIMARY TUMOR; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

HUMANS; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84868191132     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2562-5     Document Type: Review

References (18)

1. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-99.
2. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976-83. (Pubitemid 29109331)
3. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17. (Pubitemid 44465459)
4. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372: 117-26. (Pubitemid 351952257)
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma. Version v1.2013, 2012.
6. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. J Clin Oncol. 2012. doi:10.1200/JCO.2011.40.3519.
7. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. Ann Surg Oncol. 2012. doi:10.1245/s10434-012-2475-3.
8. Wright BE, Scheri RP, Ye X, Faries MB, Turner RR, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143:892-9 (Discussion 899-900).
9. Balch CM. Melanoma of the skin. In: Edge SB, Byrd DR, Compton CC, et al (editors). AJCC cancer staging manual. 7th edn. New York, Springer; 2009.
10. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.
11. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199-205.
12. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009;7:308-17.
13. Murali R, Scolyer RA, Thompson JF. Can we better identify thin cutaneous melanomas that are likely to metastasize and cause death? Ann Surg Oncol. [Epub ahead of print July 10, 2012].
14. Han D, Yu D, Zhao X, Marzban SS, Messina JL, et al. Sentinel node biopsy is indicated for thin melanomas C 0.76 mm. Ann Surg Oncol [Epub ahead of print July 6, 2012].
15. Caudle AS, Ross MI, Prieto VG, Warneke CL, Lee JE, et al. Mitotic rate predicts sentinel lymph node involvement in melanoma: Impact of the 7th edition AJCC melanoma staging system. Ann Surg Oncol. 2010;17(suppl 1):S8.
16. Paek SC, Griffith KA, Johnson TM, Sondak VK, Wong SL, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109: 100-8. (Pubitemid 46120199)
17. Sondak VK, Taylor JM, Sabel MS, Wang Y, Lowe L, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247-58. (Pubitemid 40486764)
18. Lawson EH, Gibbons MM, Ko CY. Appropriate use of surgical procedures for patients with cancer. Surg Oncol Clin North Am. 2012;21:479-86.